# Intermediate-Size Expanded Access Protocol (EAP) for LP352

> **NCT06149663** · — · AVAILABLE · sponsor: **Longboard Pharmaceuticals**

## Conditions studied

- Dravet Syndrome
- Lennox Gastaut Syndrome
- Developmental and Epileptic Encephalopathies

## Interventions

- **DRUG:** LP352

## Key facts

- **NCT ID:** NCT06149663
- **Lead sponsor:** Longboard Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06149663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06149663, "Intermediate-Size Expanded Access Protocol (EAP) for LP352". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06149663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*